LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A 22 MONTH, OPEN-LABEL EXTENSION STUDY

被引:0
|
作者
Pikalov, Andrei [1 ]
Correll, Christoph [2 ]
Cucchiaro, Josephine [1 ]
Silva, Robert [1 ]
Hsu, Jay [1 ]
Loebel, Antony [1 ]
机构
[1] Sunov Pharmaceut Inc, Marlborough, MA USA
[2] Zucker Hillside Hosp, North Shore Long Isl Jewish Hlth Syst, Psychiat Res, Glen Oaks, NY USA
关键词
D O I
10.1016/S0920-9964(14)70524-9
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
S245
引用
收藏
页码:S178 / S178
页数:1
相关论文
共 50 条
  • [1] LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A 22 MONTH, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Cucchiaro, J.
    Silva, R.
    Hsu, J.
    Pikalov, A.
    Loebel, A.
    [J]. EUROPEAN PSYCHIATRY, 2014, 29
  • [2] Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study
    Correll, Christoph U.
    Cucchiaro, Josephine
    Silva, Robert
    Hsu, Jay
    Pikalov, Andrei
    Loebel, Antony
    [J]. CNS SPECTRUMS, 2016, 21 (05) : 393 - 402
  • [3] LONG-TERM SAFETY AND TOLERABILITY OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA: RESULTS OF A 6-MONTH, OPEN-LABEL STUDY
    Stahl, Steven M.
    Cucchiaro, Josephine
    Simonelli, D.
    Severs, J.
    Loebel, A.
    [J]. SCHIZOPHRENIA BULLETIN, 2011, 37 : 322 - 322
  • [4] EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    Coghill, D.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 105 - 105
  • [5] Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Takai, Kentaro
    Higuchi, Teruhiko
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 2683 - 2695
  • [6] Effectiveness of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study
    Tocco, M.
    Arango, C.
    Correll, C. U.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1100 - S1101
  • [7] Safety of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study
    Correll, C. U.
    Arango, C.
    Tocco, M.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1099 - S1099
  • [8] SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
    Tocco, M.
    Correll, C.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 154 - 155
  • [9] SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
    Tocco, M.
    Correll, C.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 136 - 136
  • [10] Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study
    Higuchi, Teruhiko
    Ishigooka, Jun
    Iyo, Masaomi
    Hagi, Katsuhiko
    [J]. ASIA-PACIFIC PSYCHIATRY, 2020, 12 (01)